Literature DB >> 23203386

Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays.

Ju Hyun Shim1, Han Chu Lee, Seungbong Han, Hyo Jeong Kang, Eunsil Yu, Sung-Gyu Lee.   

Abstract

We retrospectively investigated the prognostic value of hepatocyte nuclear factor 1 (HNF1) proteins in 159 liver transplant patients with hepatocellular carcinoma (HCC), including 36 (22.6%) exceeding the Milan criteria. The expression of alpha-fetoprotein (AFP), HNF1α, and HNF1β was examined with immunohistochemistry on duplicate tissue microarray slides containing HCC tumor explants. The times to recurrence and cancer death were analyzed with a Cox regression model and were compared according to the expression of markers of interest. We compared risk predictions with area under the receiver operator curves (AUROCs) and C statistics. AFP, HNF1α, and HNF1β were positive in 22.6%, 46.5%, and 61.0% of the tumor immunoprofiles, respectively. Although several variables were associated with the times to recurrence and cancer death in univariate Cox analyses, only AFP expression for the time to recurrence and the Milan criteria and HNF1β expression for the times to recurrence and cancer death remained significant after multivariate adjustments. The expression of HNF1β (but not HNF1α) was related to a serum AFP level ≥ 200 ng/mL, microvascular invasion, and AFP expression (P < 0.05 for all). A subgroup analysis showed that in the group meeting the Milan criteria, recurrence and cancer death rates at 10 years in the HNF1β-negative patients were approximately one-tenth of those in the HNF1β-positive patients, but the difference was not significant in the group exceeding the Milan criteria. The addition of HNF1β expression to the Milan criteria increased the C statistics and AUROCs for both recurrence and mortality (P < 0.05 for all). In conclusion, the immunohistological detection of HNF1β predicts recurrence and HCC-specific death after transplantation and provides an additive benefit in comparison with the Milan selection criteria on their own.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23203386     DOI: 10.1002/lt.23584

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  11 in total

Review 1.  Hepatocyte Nuclear Factor 1β-Associated Kidney Disease: More than Renal Cysts and Diabetes.

Authors:  Jacobien C Verhave; Anneke P Bech; Jack F M Wetzels; Tom Nijenhuis
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

2.  Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma.

Authors:  Hyung-Don Kim; Gi-Won Song; Ju Hyun Shim; Seungbong Han; Jihyun An; Deok-Bog Moon; Kang Mo Kim; Young-Suk Lim; Gi-Young Ko; Shin Hwang; Han Chu Lee; Eunsil Yu; Kyu-Bo Sung; Sung-Gyu Lee
Journal:  Hepatol Int       Date:  2017-01-31       Impact factor: 6.047

3.  Expression of bile duct transcription factor HNF1β predicts early tumor recurrence and is a stage-independent prognostic factor in hepatocellular carcinoma.

Authors:  Ray-Hwang Yuan; Hong-Shiee Lai; Hey-Chi Hsu; Po-Lin Lai; Yung-Ming Jeng
Journal:  J Gastrointest Surg       Date:  2014-07-23       Impact factor: 3.452

4.  Overexpression Of Hepatocyte Nuclear Factor-1beta Predicting Poor Prognosis Is Associated With Biliary Phenotype In Patients With Hepatocellular Carcinoma.

Authors:  Dan-Dan Yu; Ying-Ying Jing; Shi-Wei Guo; Fei Ye; Wen Lu; Quan Li; Yu-Long Dong; Lu Gao; Yu-Ting Yang; Yang Yang; Meng-Chao Wu; Li-Xin Wei
Journal:  Sci Rep       Date:  2015-08-27       Impact factor: 4.379

Review 5.  Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction.

Authors:  Masaki Mandai; Yasuaki Amano; Ken Yamaguchi; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal:  Oncotarget       Date:  2015-10-13

Review 6.  A review on hepatocyte nuclear factor-1beta and tumor.

Authors:  Dan-Dan Yu; Shi-Wei Guo; Ying-Ying Jing; Yu-Long Dong; Li-Xin Wei
Journal:  Cell Biosci       Date:  2015-10-13       Impact factor: 7.133

7.  Hepatocyte nuclear factor-1beta enhances the stemness of hepatocellular carcinoma cells through activation of the Notch pathway.

Authors:  Jing-Ni Zhu; Lu Jiang; Jing-Hua Jiang; Xue Yang; Xiao-Yong Li; Jian-Xin Zeng; Rong-Yu Shi; Yang Shi; Xiao-Rong Pan; Zhi-Peng Han; Li-Xin Wei
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

Review 8.  Hepatocyte nuclear factor 1 beta: A perspective in cancer.

Authors:  Shubhra Chandra; Srilakshmi Srinivasan; Jyotsna Batra
Journal:  Cancer Med       Date:  2021-02-13       Impact factor: 4.452

9.  ZIP4, a novel determinant of tumor invasion in hepatocellular carcinoma, contributes to tumor recurrence after liver transplantation.

Authors:  Xiao Xu; Hai-Jun Guo; Hai-Yang Xie; Jie Li; Run-Zhou Zhuang; Qi Ling; Lin Zhou; Xu-Yong Wei; Zhi-Kun Liu; Song-Ming Ding; Kang-Jie Chen; Zhi-Yuan Xu; Shu-Sen Zheng
Journal:  Int J Biol Sci       Date:  2014-02-11       Impact factor: 6.580

10.  Integrative Analysis of HNF1B mRNA in Human Cancers Based on Data Mining.

Authors:  Chunhui Nie; Bei Wang; Baoquan Wang; Ning Lv; Enfan Zhang
Journal:  Int J Med Sci       Date:  2020-10-18       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.